This HTML5 document contains 236 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/AHFS/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/pubchem-compound/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/drugbank/
n21http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/national-drug-code-directory/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/chemspider/
n13http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00956/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00956
rdf:type
n3:Drug
n3:description
Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. [PubChem]
n3:dosage
n29:271B42C8-363D-11E5-9242-09173F13E4C5 n29:271B42C9-363D-11E5-9242-09173F13E4C5 n29:271B42C0-363D-11E5-9242-09173F13E4C5 n29:271B42C1-363D-11E5-9242-09173F13E4C5 n29:271B42C2-363D-11E5-9242-09173F13E4C5 n29:271B42C3-363D-11E5-9242-09173F13E4C5 n29:271B42C4-363D-11E5-9242-09173F13E4C5 n29:271B42C5-363D-11E5-9242-09173F13E4C5 n29:271B42C6-363D-11E5-9242-09173F13E4C5 n29:271B42C7-363D-11E5-9242-09173F13E4C5
n3:group
approved illicit
n3:halfLife
1.25-3 hours
n3:indication
For relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.
owl:sameAs
n9:DB00956 n21:DB00956
dcterms:title
Hydrocodone
adms:identifier
n11:Hydrocodone n12:16590-276 n14:5779 n15:4447623 n16:5284569 n17:46506225 n18:C08024 n19:PA449900 n20:DB00956
n3:mechanismOfAction
Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
n3:packager
n4:271B428A-363D-11E5-9242-09173F13E4C5 n4:271B428B-363D-11E5-9242-09173F13E4C5 n4:271B4288-363D-11E5-9242-09173F13E4C5 n4:271B4289-363D-11E5-9242-09173F13E4C5 n4:271B428E-363D-11E5-9242-09173F13E4C5 n4:271B428F-363D-11E5-9242-09173F13E4C5 n4:271B428C-363D-11E5-9242-09173F13E4C5 n4:271B428D-363D-11E5-9242-09173F13E4C5 n4:271B4282-363D-11E5-9242-09173F13E4C5 n4:271B4283-363D-11E5-9242-09173F13E4C5 n4:271B425D-363D-11E5-9242-09173F13E4C5 n4:271B4281-363D-11E5-9242-09173F13E4C5 n4:271B4286-363D-11E5-9242-09173F13E4C5 n4:271B4287-363D-11E5-9242-09173F13E4C5 n4:271B4284-363D-11E5-9242-09173F13E4C5 n4:271B4285-363D-11E5-9242-09173F13E4C5 n4:271B4257-363D-11E5-9242-09173F13E4C5 n4:271B4258-363D-11E5-9242-09173F13E4C5 n4:271B4255-363D-11E5-9242-09173F13E4C5 n4:271B4256-363D-11E5-9242-09173F13E4C5 n4:271B4278-363D-11E5-9242-09173F13E4C5 n4:271B425B-363D-11E5-9242-09173F13E4C5 n4:271B4279-363D-11E5-9242-09173F13E4C5 n4:271B425C-363D-11E5-9242-09173F13E4C5 n4:271B4275-363D-11E5-9242-09173F13E4C5 n4:271B4259-363D-11E5-9242-09173F13E4C5 n4:271B4277-363D-11E5-9242-09173F13E4C5 n4:271B425A-363D-11E5-9242-09173F13E4C5 n4:271B427F-363D-11E5-9242-09173F13E4C5 n4:271B424F-363D-11E5-9242-09173F13E4C5 n4:271B4280-363D-11E5-9242-09173F13E4C5 n4:271B4250-363D-11E5-9242-09173F13E4C5 n4:271B427A-363D-11E5-9242-09173F13E4C5 n4:271B424D-363D-11E5-9242-09173F13E4C5 n4:271B427B-363D-11E5-9242-09173F13E4C5 n4:271B424E-363D-11E5-9242-09173F13E4C5 n4:271B4253-363D-11E5-9242-09173F13E4C5 n4:271B4254-363D-11E5-9242-09173F13E4C5 n4:271B4251-363D-11E5-9242-09173F13E4C5 n4:271B4270-363D-11E5-9242-09173F13E4C5 n4:271B4252-363D-11E5-9242-09173F13E4C5 n4:271B4247-363D-11E5-9242-09173F13E4C5 n4:271B4274-363D-11E5-9242-09173F13E4C5 n4:271B4248-363D-11E5-9242-09173F13E4C5 n4:271B4245-363D-11E5-9242-09173F13E4C5 n4:271B426F-363D-11E5-9242-09173F13E4C5 n4:271B4246-363D-11E5-9242-09173F13E4C5 n4:271B424B-363D-11E5-9242-09173F13E4C5 n4:271B424C-363D-11E5-9242-09173F13E4C5 n4:271B4249-363D-11E5-9242-09173F13E4C5 n4:271B424A-363D-11E5-9242-09173F13E4C5 n4:271B4240-363D-11E5-9242-09173F13E4C5 n4:271B4243-363D-11E5-9242-09173F13E4C5 n4:271B4244-363D-11E5-9242-09173F13E4C5 n4:271B4241-363D-11E5-9242-09173F13E4C5 n4:271B4242-363D-11E5-9242-09173F13E4C5 n4:271B42B0-363D-11E5-9242-09173F13E4C5 n4:271B425E-363D-11E5-9242-09173F13E4C5 n4:271B425F-363D-11E5-9242-09173F13E4C5 n4:271B42AA-363D-11E5-9242-09173F13E4C5 n4:271B42AB-363D-11E5-9242-09173F13E4C5 n4:271B42A8-363D-11E5-9242-09173F13E4C5 n4:271B42A9-363D-11E5-9242-09173F13E4C5 n4:271B42AE-363D-11E5-9242-09173F13E4C5 n4:271B42AF-363D-11E5-9242-09173F13E4C5 n4:271B42AC-363D-11E5-9242-09173F13E4C5 n4:271B42AD-363D-11E5-9242-09173F13E4C5 n4:271B42A2-363D-11E5-9242-09173F13E4C5 n4:271B42A3-363D-11E5-9242-09173F13E4C5 n4:271B42A0-363D-11E5-9242-09173F13E4C5 n4:271B42A1-363D-11E5-9242-09173F13E4C5 n4:271B42A6-363D-11E5-9242-09173F13E4C5 n4:271B42A7-363D-11E5-9242-09173F13E4C5 n4:271B42A4-363D-11E5-9242-09173F13E4C5 n4:271B42A5-363D-11E5-9242-09173F13E4C5 n4:271B429A-363D-11E5-9242-09173F13E4C5 n4:271B429B-363D-11E5-9242-09173F13E4C5 n4:271B4298-363D-11E5-9242-09173F13E4C5 n4:271B4299-363D-11E5-9242-09173F13E4C5 n4:271B429E-363D-11E5-9242-09173F13E4C5 n4:271B429F-363D-11E5-9242-09173F13E4C5 n4:271B429C-363D-11E5-9242-09173F13E4C5 n4:271B429D-363D-11E5-9242-09173F13E4C5 n4:271B4292-363D-11E5-9242-09173F13E4C5 n4:271B4293-363D-11E5-9242-09173F13E4C5 n4:271B4290-363D-11E5-9242-09173F13E4C5 n4:271B4291-363D-11E5-9242-09173F13E4C5 n4:271B4296-363D-11E5-9242-09173F13E4C5 n4:271B4297-363D-11E5-9242-09173F13E4C5 n4:271B4294-363D-11E5-9242-09173F13E4C5 n4:271B4295-363D-11E5-9242-09173F13E4C5 n4:271B426E-363D-11E5-9242-09173F13E4C5 n4:271B4266-363D-11E5-9242-09173F13E4C5 n4:271B4267-363D-11E5-9242-09173F13E4C5 n4:271B4264-363D-11E5-9242-09173F13E4C5 n4:271B4265-363D-11E5-9242-09173F13E4C5 n4:271B426C-363D-11E5-9242-09173F13E4C5 n4:271B426D-363D-11E5-9242-09173F13E4C5 n4:271B4268-363D-11E5-9242-09173F13E4C5 n4:271B426B-363D-11E5-9242-09173F13E4C5 n4:271B4262-363D-11E5-9242-09173F13E4C5 n4:271B4263-363D-11E5-9242-09173F13E4C5 n4:271B4261-363D-11E5-9242-09173F13E4C5 n4:271B427D-363D-11E5-9242-09173F13E4C5 n4:271B427E-363D-11E5-9242-09173F13E4C5 n4:271B426A-363D-11E5-9242-09173F13E4C5 n4:271B4271-363D-11E5-9242-09173F13E4C5 n4:271B4260-363D-11E5-9242-09173F13E4C5 n4:271B4269-363D-11E5-9242-09173F13E4C5 n4:271B4276-363D-11E5-9242-09173F13E4C5 n4:271B427C-363D-11E5-9242-09173F13E4C5 n4:271B4272-363D-11E5-9242-09173F13E4C5 n4:271B4273-363D-11E5-9242-09173F13E4C5
n3:synonym
Idrocodone Hydroconum Hydrocodone (-)-Dihydrocodeinone Hidrocodona Hydrocone 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one Dihydrocodeinone Hydrocodon Hydrocodonum
n3:toxicity
Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD<sub>50</sub>=85.7mg/kg (subcutaneous, in mice).
n24:hasAHFSCode
n28:48-08-00
n3:foodInteraction
Take with food. To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables). Avoid alcohol.
n3:mixture
n7:271B423F-363D-11E5-9242-09173F13E4C5 n7:271B423B-363D-11E5-9242-09173F13E4C5 n7:271B423E-363D-11E5-9242-09173F13E4C5 n7:271B4239-363D-11E5-9242-09173F13E4C5 n7:271B423A-363D-11E5-9242-09173F13E4C5 n7:271B4227-363D-11E5-9242-09173F13E4C5 n7:271B4226-363D-11E5-9242-09173F13E4C5 n7:271B423C-363D-11E5-9242-09173F13E4C5 n7:271B423D-363D-11E5-9242-09173F13E4C5 n7:271B422F-363D-11E5-9242-09173F13E4C5 n7:271B4230-363D-11E5-9242-09173F13E4C5 n7:271B422D-363D-11E5-9242-09173F13E4C5 n7:271B422E-363D-11E5-9242-09173F13E4C5 n7:271B422B-363D-11E5-9242-09173F13E4C5 n7:271B422C-363D-11E5-9242-09173F13E4C5 n7:271B4229-363D-11E5-9242-09173F13E4C5 n7:271B422A-363D-11E5-9242-09173F13E4C5 n7:271B4237-363D-11E5-9242-09173F13E4C5 n7:271B4238-363D-11E5-9242-09173F13E4C5 n7:271B4235-363D-11E5-9242-09173F13E4C5 n7:271B4236-363D-11E5-9242-09173F13E4C5 n7:271B4233-363D-11E5-9242-09173F13E4C5 n7:271B4234-363D-11E5-9242-09173F13E4C5 n7:271B4231-363D-11E5-9242-09173F13E4C5 n7:271B4232-363D-11E5-9242-09173F13E4C5 n7:271B4228-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
n3:synthesisReference
Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.
n26:hasConcept
n27:M0010704
foaf:page
n23:hydrocod.htm
n3:IUPAC-Name
n13:271B42CE-363D-11E5-9242-09173F13E4C5
n3:InChI
n13:271B42D4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n13:271B42D3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B42D0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n13:271B42D1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n13:271B42D2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n13:271B42CC-363D-11E5-9242-09173F13E4C5 n13:271B42E4-363D-11E5-9242-09173F13E4C5
n3:logP
n13:271B42CA-363D-11E5-9242-09173F13E4C5 n13:271B42CD-363D-11E5-9242-09173F13E4C5 n13:271B42E6-363D-11E5-9242-09173F13E4C5
n3:logS
n13:271B42CB-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:R05DA03
n3:H-Bond-Acceptor-Count
n13:271B42DA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n13:271B42DB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n13:271B42D5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n13:271B42D6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n13:271B42D8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n13:271B42D7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n13:271B42D9-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
125-29-1
n3:category
n3:containedIn
n5:271B42BE-363D-11E5-9242-09173F13E4C5 n5:271B42BF-363D-11E5-9242-09173F13E4C5 n5:271B42BC-363D-11E5-9242-09173F13E4C5 n5:271B42BD-363D-11E5-9242-09173F13E4C5 n5:271B42B6-363D-11E5-9242-09173F13E4C5 n5:271B42B7-363D-11E5-9242-09173F13E4C5 n5:271B42B3-363D-11E5-9242-09173F13E4C5 n5:271B42B5-363D-11E5-9242-09173F13E4C5 n5:271B42BA-363D-11E5-9242-09173F13E4C5 n5:271B42BB-363D-11E5-9242-09173F13E4C5 n5:271B42B8-363D-11E5-9242-09173F13E4C5 n5:271B42B9-363D-11E5-9242-09173F13E4C5 n5:271B42B1-363D-11E5-9242-09173F13E4C5 n5:271B42B2-363D-11E5-9242-09173F13E4C5 n5:271B42B4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n13:271B42E0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n13:271B42E2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n13:271B42E3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B42E5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n13:271B42DF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n13:271B42DE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n13:271B42E1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n13:271B42CF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n13:271B42DC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n13:271B42DD-363D-11E5-9242-09173F13E4C5